Objective:

To evaluate the methods, nature, quality of results, and potential benefits of microbiome analyses offered by French laboratories, specifically noting the lack of initial medical advice.

Key Findings:

• High degree of heterogeneity in kit content and procedures across laboratories.
• Significant variations in report types, lengths, and regulatory compliance.
• Contradictory interpretations of microbiome data and unsubstantiated health claims.
• Health recommendations were often non-personalised and based on unreferenced sources.
• Concerns regarding conflicts of interest between laboratories and pharmaceutical companies.

Interpretation:

The study highlights a lack of standardization, transparency, and clinical validation in microbiome testing kits, posing risks of misinformation for consumers and challenges for healthcare providers interpreting such data.

Limitations:

• The study only included five laboratories, which may not represent the entire market.
• The fictitious patient scenario may not capture real-world variability in patient demographics and conditions, potentially affecting the findings.

Conclusion:

Enhanced regulatory oversight, method validation, and integration of microbiome science into medical education are necessary to improve test reliability and foster trust in microbiome diagnostics.